Skip to main content

Peer Review reports

From: Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma

Original Submission
12 Nov 2017 Submitted Original manuscript
6 Dec 2017 Reviewed Reviewer Report - Eva Fischer-Fodor
27 Dec 2017 Reviewed Reviewer Report - Philipp Ivanyi
18 Jan 2018 Author responded Author comments - Aniko Maraz
Resubmission - Version 2
18 Jan 2018 Submitted Manuscript version 2
4 Mar 2018 Author responded Author comments - Aniko Maraz
Resubmission - Version 3
4 Mar 2018 Submitted Manuscript version 3
Publishing
9 Mar 2018 Editorially accepted
15 Mar 2018 Article published 10.1186/s12885-018-4209-9

You can find further information about peer review here.

Back to article page